Assembly Biosciences, Inc. ASMB
Set alert
20.13 USD -0.73 -3.50%
At close · Oct 30
20.13 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
19.98 Day range 21.00
19.30 52-week range 39.71
- YTD
- -40.81%
- 1 year
- -33.17%
- Open
- 20.86
- Prev close
- 20.86
- Mkt cap
- 409.86M
- Vol
- 136.87K
- Avg vol
- 292.54K
- EPS
- 1.04
- P/E
- 19.36
- Div yield
- 0.00%
More statistics
- Low
- 19.98
- High
- 21.00
- Forward P/E
- -2.12
- Beta
- 0.59
- Short ratio
- 0.41
- Inst. own
- 18.79%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 27, 2024
- 50-d avg
- 16.31
- 200-d avg
- 15.02
- 1y target
- 35.50
News
-
3 days ago benzinga.com
Assembly Biosciences Doses First Two Patients In Its Phase 2 Clinical Trial Of ABI-6250 To Treat Chronic Hepatitis Delta Virus Infection
Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced dosing of the first two participants…
3 days ago globenewswire.com
Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
– Phase 2 study will evaluate the safety, pharmacokinetics and antiviral activity of ABI-6250 in participants with chronic HDV infection – – Initial data from the Phase 2 study is expected in the…
-
3 weeks ago benzinga.com
Assembly Biosciences To Present New Phase 1a Data From Its ABI-6250 Program At The Liver Meeting 2026
Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced that two posters featuring new Phase…